Circulation, Vol 77, 787-794, Copyright © 1988 by American Heart Association
JD Horowitz, CA Henry, ML Syrjanen, WJ Louis, RD Fish, TW Smith and EM Antman
The vasodilator effects of nitroglycerin (NTG) are mediated via activation
of guanylate cyclase; this process is believed to require the availability
of free sulfhydryl groups. Previous studies in man have shown that the
sulfhydryl donor N-acetylcysteine (NAC) potentiates the systemic and
coronary vasodilator effects of NTG. Furthermore, interaction of NTG and
NAC may lead to the formation of S-nitroso-NAC, which strongly inhibits
platelet aggregation. The effects of intravenous NTG combined with
intravenous NAC (5 g 6 hourly) were compared with those of intravenous NTG
alone in a double-blind trial in 46 patients with severe unstable angina
pectoris unresponsive to conventional treatment, which included calcium
antagonists and cutaneous nitrates in all but one patient. Treatment with
NTG/NAC (24 patients) and that with NTG alone (22 patients) was associated
with a similar frequency of episodes of chest pain and of increments in NTG
infusion rate for pain control (10 vs 17; p = NS). The NTG/NAC group had a
significantly lower incidence of acute myocardial infarction than the
NTG/placebo group (three vs 10 patients; p = .013). Symptomatic hypotension
occurred frequently in the NTG/NAC group (seven vs 0 patients; p = .006).
Lactate-pyruvate ratios and venous NTG concentrations were not
significantly affected by NAC. Subsequently, another 20 consecutive
patients were treated with intravenous NTG and continuously infused NAC (10
g/day). Seven remained pain free during the first 24 hr of NTG infusion; 11
required increments in NTG infusion rate for pain control. Acute myocardial
infarction occurred in one patient, while none developed symptomatic
hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris
Department of Cardiology, Austin Hospital, Heidelberg, Victoria, Australia.
This article has been cited by other articles:
![]() |
M. Ozaydin, O. Peker, D. Erdogan, S. Kapan, Y. Turker, E. Varol, F. Ozguner, A. Dogan, and E. Ibrisim N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study Eur. Heart J., March 1, 2008; 29(5): 625 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sochman N-acetylcysteine in acute cardiology: 10 years later: What do we know and what would we like to know?! J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1422 - 1428. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. Andrews, A. Prasad, and A. A. Quyyumi N-acetylcysteine improves coronary and peripheral vascular function J. Am. Coll. Cardiol., January 1, 2001; 37(1): 117 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Prasad, N. P. Andrews, F. A. Padder, M. Husain, and A. A. Quyyumi Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability J. Am. Coll. Cardiol., August 1, 1999; 34(2): 507 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hebert, J.-X. Xiang, and J. Y.T. Lam Persistent Inhibition of Platelets During Continuous Nitroglycerin Therapy Despite Hemodynamic Tolerance Circulation, March 4, 1997; 95(5): 1308 - 1313. [Abstract] [Full Text] |
||||
![]() |
M. A. Arstall, J. Yang, I. Stafford, W. H. Betts, and J. D. Horowitz N-Acetylcysteine in Combination With Nitroglycerin and Streptokinase for the Treatment of Evolving Acute Myocardial Infarction : Safety and Biochemical Effects Circulation, November 15, 1995; 92(10): 2855 - 2862. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1988 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |